InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
midastouch017 Free
03/28/24 8:56 AM
profile icon
midastouch017 Free
03/11/24 9:14 AM
profile icon
midastouch017 Free
02/28/24 1:15 PM
profile icon
midastouch017 Free
01/30/24 8:02 AM
profile icon
midastouch017 Free
01/29/24 8:05 AM
profile icon
midastouch017 Free
12/20/23 8:03 AM
profile icon
midastouch017 Free
12/18/23 7:18 AM
profile icon
midastouch017 Free
12/04/23 7:52 AM
profile icon
midastouch017 Free
11/30/23 8:04 AM
profile icon
midastouch017 Free
11/21/23 2:15 PM
profile icon
midastouch017 Free
11/21/23 8:03 AM
profile icon
midastouch017 Free
11/01/23 8:46 AM
profile icon
midastouch017 Free
10/30/23 8:51 AM
profile icon
midastouch017 Free
10/26/23 8:32 AM
profile icon
midastouch017 Free
10/09/23 7:52 AM
profile icon
midastouch017 Free
09/27/23 8:01 AM
profile icon
midastouch017 Free
09/07/23 8:21 AM
profile icon
midastouch017 Free
09/02/23 1:09 AM
profile icon
midastouch017 Free
08/31/23 7:47 AM
profile icon
midastouch017 Free
08/24/23 8:01 AM
profile icon
midastouch017 Free
08/18/23 8:02 AM
profile icon
midastouch017 Free
08/09/23 8:00 AM
profile icon
midastouch017 Free
08/01/23 12:31 AM
profile icon
midastouch017 Free
07/17/23 8:07 AM
profile icon
midastouch017 Free
07/07/23 8:12 AM
profile icon
midastouch017 Free
06/29/23 7:43 AM
profile icon
midastouch017 Free
06/13/23 8:18 AM
profile icon
midastouch017 Free
06/13/23 8:10 AM
profile icon
midastouch017 Free
06/08/23 9:02 AM
profile icon
midastouch017 Free
06/02/23 8:17 AM
profile icon
midastouch017 Free
06/01/23 8:25 AM
profile icon
midastouch017 Free
05/30/23 8:22 AM
profile icon
midastouch017 Free
05/15/23 9:24 AM
profile icon
midastouch017 Free
05/10/23 1:43 PM
profile icon
midastouch017 Free
05/09/23 11:26 PM
profile icon
murocman Free
05/09/23 10:45 PM
profile icon
midastouch017 Free
05/09/23 4:26 PM
profile icon
murocman Free
05/09/23 4:16 PM
profile icon
murocman Free
05/09/23 2:13 PM
profile icon
midastouch017 Free
05/09/23 8:45 AM
profile icon
midastouch017 Free
05/02/23 8:36 AM
profile icon
midastouch017 Free
04/24/23 7:55 AM
profile icon
midastouch017 Free
04/10/23 8:34 AM
profile icon
midastouch017 Free
03/30/23 8:06 AM
profile icon
midastouch017 Free
03/30/23 7:59 AM
profile icon
midastouch017 Free
03/30/23 7:53 AM
profile icon
midastouch017 Free
03/17/23 10:56 AM
profile icon
oil export Free
03/17/23 10:10 AM

Can Fite BioPharma Ltd (CANF) RSS Feed

Followers
66
Posters
222
Posts (Today)
0
Posts (Total)
2020
Created
10/11/12
Type
Free
Moderators midastouch017

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and liver diseases.

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects

 
 

The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. Piclidenoson (CF101), Can-Fite`s lead drug candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the Phase II/III clinical studies in Psoriasis showed clinical activity and safety of the drug. Namodenoson (CF102), Can-Fite`s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). CF602 an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of sexual dysfunction. Can-Fite has a wealth of clinical experience which includes over 1200 patients who have participated in clinical trials conducted by the company.

Can-Fite has licensed Piclidenoson for the treatment of autoimmune diseases to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria,  for RA to Kwang Dong in Korea and to CMS for RA and Psoriasis in China, Taiwan, Hong Kong, Macao.

Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.

Can-Fite is collaborating with leading researchers from the US NIH and the Leiden University in the Netherlands.

 

Israeli Office

10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
ISRAEL (Directions)

Tel: +972-3-9241114
Fax: +972-3-9249378

General email:
info@canfite.co.il

 

Investor Relations
(800)716-4880
info@canfite.co.il 


 

USA Office

255 Bear Hill Road, Suite 2200
Waltham
MA 02451
USA

Tel: +972-3-9241114
Fax: +972-3-9249378

http://www.canfite.com/

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post